Prostate Cancer Clinical Trial
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.
Diagnosis of metastatic (Stage IV) prostate cancer (PC), confirmed by either biopsy of a metastatic tumor site or history of localized disease supported by metastatic disease on imaging studies (that is [i.e.], clearly noted in hospital/clinical records)
Signed Informed consent form (ICF)
No condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example [e.g.], compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Willing to provide a saliva, blood, and/or archival tumor tissue sample for genomic analysis
No prior poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor (PARPi) for the treatment of prostate cancer
No prior DNA-repair gene defect test results from a Janssen sponsored interventional trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 330 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.